| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,468,712 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$12,468,712 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-15 |
4 |
AS |
$274.98 |
$23,318 |
D/D |
(82) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-03 |
4 |
AS |
$276.84 |
$648,290 |
D/D |
(2,330) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-06 |
4 |
AS |
$270.12 |
$331,663 |
D/D |
(1,223) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-11-16 |
4 |
AS |
$222.45 |
$8,492 |
D/D |
(38) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-23 |
4 |
D |
$431.79 |
$1,714,206 |
D/D |
(3,970) |
30,052 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-06 |
4 |
OE |
$155.57 |
$190,107 |
D/D |
1,222 |
30,124 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-06 |
4 |
OE |
$155.57 |
$190,262 |
D/D |
1,223 |
30,125 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-12 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
30,206 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-04 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
31,232 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-03 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
31,232 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-19 |
4 |
AS |
$186.81 |
$1,051,716 |
D/D |
(5,624) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-05-15 |
4 |
AS |
$165.41 |
$15,052 |
D/D |
(91) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
AS |
$186.37 |
$2,329,976 |
D/D |
(12,501) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
AS |
$194.37 |
$713,144 |
D/D |
(3,669) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
AS |
$200.26 |
$827,049 |
D/D |
(4,126) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-06 |
4 |
AS |
$196.08 |
$241,189 |
D/D |
(1,223) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-15 |
4 |
AS |
$205.95 |
$12,357 |
D/D |
(60) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
AS |
$219.37 |
$857,737 |
D/D |
(3,910) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
AS |
$229.35 |
$953,861 |
D/D |
(4,126) |
31,553 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
31,930 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-27 |
4 |
AS |
$287.23 |
$1,218,449 |
D/D |
(4,238) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-08-09 |
4 |
AS |
$345.51 |
$21,767 |
D/D |
(63) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-11-15 |
4 |
AS |
$369.92 |
$7,028 |
D/D |
(19) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-06 |
4 |
OE |
$155.57 |
$190,262 |
D/D |
1,223 |
32,776 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-25 |
4 |
AS |
$211.58 |
$646,139 |
D/D |
(3,028) |
33,589 |
0 |
% |
|
157 Records found
|
|
Page 2 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
